

IN THE CLAIMS

Please replace claims 1, 11 and 17 with the following amended claims.

23
1. (Twice Amended) A composition comprising immunosuppressants, cyclosporins, FK506, or rapamycin and at least one bioactive peptide corresponding to the high-affinity binding/anti-lymphoproliferative site of interferons α , β , ω , τ , or recombinant proteins carrying one or more of the sequences corresponding to the structures of the bioactive peptides corresponding to the high-affinity binding/anti-lymphoproliferative site of the said interferons for the aim of amplification of immunosuppressants' activities to decrease their therapeutic dose, and as the consequence to avoid their undesirable side effects during organ and tissue transplantation or during treatment of cancers such as lymphomas, leukemias, myelomas, adenocarcinomas, autoimmune and chronic inflammatory diseases, such as rheumatoid arthritis, myasthenia gravis, lupus erythematosus, uveitis, hyperproliferative diseases, such as psoriasis vulgaris, wherein cyclosporins, FK506 or rapamycin can be exploited.

C 24
~~11. (Amended) The composition according to claim 6, wherein the at least one bioactive polypeptide is α -peptoferron, albeferron, or a mixture thereof.~~

25
17. (Amended) The method according to claim 12, wherein the at least one bioactive polypeptide is α -peptoferron, albeferron, or a mixture thereof.